SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biomatrix (BXM) Looking Great

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kenny who wrote (72)9/8/1997 10:47:00 PM
From: John McCarthy   of 569
 
Kenny -

BIOX will *NEVER* realize a billion dollars in Gross Revenues,
Gross Sales, or whatever you want to call the TOP LINE NUMBER.

The distribution companies - RPR,AHP,ROCHE,BI, and Bayer
collectively - it is thought by the author of the comment -
may reach a BILLION dollars in Gross Sales.

As best I understand it, final pricing was still up in the
air as of a couple of weeks ago, but the best guess was that
BIOX'S Gross Sales would equal $30.00 (thirty-dollars) * (times)
each vial of product sold to those distribution companies listed above.

Note:I am assuming 1 Vial = 1 Needles worth

Some people expect them to make about $100 million in
Gross Revenues (Sales) if the product does well.

Don't get me wrong.

BIOX is my largest holding.

So I am rootin for it too.

But just wanted you to have the facts, as best I understand
them.

BTW

If Bayer licenses Synvisc from BIOX for the distribution rights
to China, in my DUMB OPINION, they pay $25.0 - $35.0 million.
As I know you know, BIOX only has about 11 million shares
outstanding.

Regards,

John McCarthy
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext